The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study

Table 1 Asthmatic participants demographics

Participant	Gender	Age (years)	Height (cm)	BMI (kg/m²)	Mean FEV₁/ FVC	Mean Baseline FEV₁ (L)	Mean Baseline FEV₁ (% Predicted)	Mean Baseline MCh PC₂₀ (mg/mL)
01	F	24	157	21	0.79	2.24	74	0.24
02	M	40	178	27	0.75	3.49	83	0.92
03	M	20	169	22	0.71	3.61	84	3.6
04	F	28	168	23	0.69	3.32	97	3.8
05	M	27	173	29	0.61	3.14	73	0.22
06	F	23	173	22	0.81	3.55	95	2.0
07	F	21	163	20	0.91	3.70	111	2.4
08	F	21	173	30	0.86	3.65	98	3.7
09	F	29	160	20	0.86	2.62	84	2.0
10	M	32	185	32	0.67	3.41	72	1.8
11	M	70	168	23	0.67	2.14	78	1.7
12	M	22	173	27	0.78	4.17	95	3.1
13	F	18	130	21	0.87	1.62	73	1.3
14	M	25	172	27	0.82	4.23	99	2.1
15	F	30	160	25	0.78	2.98	96	3.2
16	M	23	180	24	0.89	4.29	90	2.4
Means:	50% Male	28 [12]	168 [12]	25 [4]	0.78 [0.09]	3.26 [0.77]	88 [12]	2.2^a

BMI body mass index, FEV ₁ forced expiratory volume in 1 s, FVC forced vital capacity, MCh methacholine, PC ₂₀ provocative concentration of MCh causing a 20% fall in FEV₁; [], standard deviation;^a, geometric mean
Mean Baseline MCh PC₂₀ – determined by averaging the pre-treatment baseline PC₂₀’s

ISSN: 1465-993X